Literature DB >> 25688506

Impact of a program for rapid diagnosis and treatment of lung cancer on hospital care delay and tumor stage.

Anna Selva, Ignasi Bolíbar, Alfons Torrego, Maria Cinta Pallarès.   

Abstract

AIMS AND
BACKGROUND: Several countries have introduced programs for rapid diagnosis and treatment of cancer, but their impact on hospital care delay and tumor stage is not clear. We assessed the impact of a rapid diagnosis and treatment program (RDTP) for lung cancer on the diagnosis-to-treatment interval (DTI) and tumor stage. METHODS AND STUDY
DESIGN: We performed a quasi-experimental study in an intervention group of 191 patients with lung cancer attended through the RDTP circuit and a comparison group of 171 patients attended through the routine hospital circuit. Groups were matched for age and patterns of presentation. Multivariate analysis adjusting for different factors was performed.
RESULTS: The median DTI was 36 days for the RDTP group and 45 days for the comparison group (P = 0.021). More patients in the RDTP group had advanced stage illness (III-IV) than in the comparison group (P = 0.032). In the multivariate analysis, none of these associations was statistically significant. Regardless of the type of circuit, a DTI <30 days was associated with disseminated disease (OR 3.28, P = 0.003).
CONCLUSIONS: In this study, the RDTP circuit failed to reduce DTI and influence stage. Our results suggest tumor stage is the main determinant of both DTI and disease outcome.

Entities:  

Mesh:

Year:  2014        PMID: 25688506     DOI: 10.1700/1778.19286

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916            Impact factor:   2.098


  1 in total

1.  Association between time-to-treatment and outcomes in non-small cell lung cancer: a systematic review.

Authors:  Helen Hall; Adam Tocock; Sarah Burdett; David Fisher; William M Ricketts; John Robson; Thomas Round; Sarita Gorolay; Emma MacArthur; Donna Chung; Sam M Janes; Michael D Peake; Neal Navani
Journal:  Thorax       Date:  2021-08-17       Impact factor: 9.102

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.